DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/8ab7cf/chile_pharmaceutic) has announced the addition of the "Chile Pharmaceuticals and Healthcare Report Q1 2012" report to their offering.
At a value of CLP1,381bn (US$2.71bn), drug expenditure in Chile represented 1.32% of GDP in 2010, while per capita spending reached an estimated US$158. Chile's economic development is forecast to experience steady modest growth. Fiscal expenditure will increase and real GDP growth is expected to come in at 5.9% in 2011, providing a solid foundation for the further growth of healthcare and pharmaceutical expenditure. In addition to healthcare modernisation and economic growth, another driver of Chile's pharmaceutical market growth is its ageing population and the increasing disease burden, especially of non-communicable conditions.
Key Trends And Developments:
- In November 2011, the US Pharmacopeial Convention (USP) signed a memorandum of understanding with the Chilean Pharmacopoeia Foundation (CPF).
- Around the same time, the executive president of the Chamber of the Pharmaceutical Industry (CIF) dismissed calls to introduce bioequivalence standards across Chile's generic drug sector, as it would ultimately lead to an increase in the price of generic drugs.
- In September 2011, a Ministry of Health audit of Chile's private insurance companies left Isapres de Chile facing 12 fines totalling CLP109mn (US$222,500).
About This Report:
Chile Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Chile's pharmaceuticals and healthcare industry.
Key Topics Covered:
- Executive Summary
- SWOT Analysis
- Pharmaceutical Business Environment Ratings
- Chile - Market Summary
- Regulatory Regime
- Industry Developments
- Industry Forecast Scenario
- Competitive Landscape
- Company Monitor
- Country Snapshot: Chile Demographic Data
- Glossary
- BMI Methodology
Companies Mentioned:
- Laboratorios Chile (LabChile)
- Corporacin Farmacutica Recalcine (CFR)
- Laboratorios Andrmaco
- Pfizer
- Novartis
- Sanofi
- GlaxoSmithKline
- Merck & Co
Reasons to Buy:
- Benchmark BMI's Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Chile to test other views - a key input for successful budgeting and strategic business planning in the Chile pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Chile Pharmaceutical and Healthcare Sector through our reviews - and major deals, projects and investments in Chile.
- Exploit The Latest Competitive Chile Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure - includes multi-national and national companies in Chile.
For more information visit http://www.researchandmarkets.com/research/8ab7cf/chile_pharmaceutic